Can Epigral’s Specialty Chemical Expansion Drive Revenue Mix to 70% by FY28?
The shares of this small cap company majorly engaged in the business of manufacturing chemicals which includes derivatives, speciality chemicals, and many more were in focus after the management targets 70% speciality chemicals revenue target.
With the market capitalization of Rs. 4,273 Crores, the shares of Epigral Ltd were trading at around Rs.991 per share which is 44 percent discount from its 52 week high of Rs. 1771 per share and is trading at a P/E of 15.7 whereas industry P/E stands at 28.6.
From Chlor-Alkali to Higher-Value Products:
Epigral is gradually changing the composition of its business by increasing the contribution of derivatives and specialty chemicals. In FY26, derivatives and specialty chemicals accounted for 48% of revenue, while the company expects this share to reach around 70% by FY28E. The shift includes products such as CPVC Resin, Epichlorohydrin (ECH), Chloromethanes and Hydrogen Peroxide, while the planned Epoxy Resin and Multi-Purpose Plant will further expand its downstream portfolio. This transition is important because it moves the company further into value-added products rather than remaining primarily dependent on its chlor-alkali portfolio.
Capacity Expansion Is Supporting the Transition:
T he company has multiple capacity projects lined up to support this change in mix. Epigral is adding 75,000 TPA of CPVC Resin and 50,000 TPA of ECH, with both projects expected to be commissioned in Q2FY27. After expansion, CPVC capacity will reach 1,50,000 TPA, which the company describes as the world's largest plant by capacity, while ECH capacity will reach 1,00,000 TPA, described as India's largest plant by capacity. Management expects domestic demand for CPVC to grow at around 12%-13% CAGR, while ECH demand is expected to grow at a high double-digit rate.
Epoxy and MPP Could Take the Downstream Strategy Further:
Beyond the near-term capacity additions, Epigral has approved a 125,000 TPA Epoxy Resin & Formulations plant and a Multi-Purpose Plant, both targeted for commissioning in H2FY28. The epoxy project is planned at the existing Dahej complex and will use ECH and Caustic Soda as key raw materials. The MPP will be downstream of the ECH and Chlorotoluenes value chain and will target pharmaceutical and agrochemical intermediates as well as water-treatment chemicals. The projects are therefore designed not only to add capacity but also to utilise Epigral's existing integrated manufacturing base.
Integration Could Be Central to the Business Model:
Epigral's expansion strategy is built around forward and backward integration, with the company using internal raw materials to manufacture higher-value downstream products. Its existing complex already links chlor-alkali products with derivatives such as ECH and CPVC. The company also highlights its focus on adding value-added products within existing value chains and entering products that are currently fully imported. This approach is intended to strengthen the integrated complex while reducing dependence on a narrower product portfolio.
Q1 Performance Provides the Current Base
The specialty-chemical transition is being pursued alongside an operating business that delivered a relatively strong Q1FY27. Revenue increased 15% YoY to ₹709 crore, while EBITDA rose 10% to ₹179 crore, with EBITDA margin at 25%. PAT increased 25% to ₹99 crore. At the same time, net debt/EBITDA stood at 0.8x as of June 30, 2026. The key question for investors is therefore how the planned capacity additions and changing product mix translate into the company's financial performance as it moves toward FY28
The move by Epigral into the specialty chemicals market will focus on modifying its mix of products through downstream capacity creation, integration, and value chain transformation. With several initiatives currently under way, the firm is gearing itself up to capture more revenues from high-end products. Execution of the above initiatives and the ability to make the targeted move into specialty chemicals will be the critical performance indicator.